Literature DB >> 7105620

Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin.

P R Jackson, G T Tucker, H F Woods.   

Abstract

Altered concentrations of serum proteins often accompany malignant disease. The effect of these changes on drug binding was studied with lidocaine, a basic drug, and tolbutamide, an acidic drug. Patients with cancer had increased serum concentrations of the acute-phase protein alpha 1-acid glycoprotein (AAG) and lowered serum concentration of albumin. In association with these changes lidocaine binding was increased at all concentrations studied (predialysis concentrations 2, 6, and 10 microgram . ml-1) and that of tolbutamide was decreased at the highest concentration (200 microgram . ml-1). Not all of the increase in lidocaine binding was explicable on the basis of increased serum AAG concentration. Estimation of binding parameters with a model with two independent sites showed increased affinity at the high affinity site in cancer patients with no change in the calculated number of binding sites. Therefore, in cancer there is increased lidocaine binding in association with increased AAG concentrations. We also record the novel observation of a change in the intrinsic properties of the high affinity binding site.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105620     DOI: 10.1038/clpt.1982.163

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein.

Authors:  B T Veering; A G Burm; J H Souverijn; J M Serree; J Spierdijk
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

4.  Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

Authors:  Oliver von Richter; Giorgio Massimini; Holger Scheible; Istvan Udvaros; Andreas Johne
Journal:  Br J Clin Pharmacol       Date:  2016-09-19       Impact factor: 4.335

5.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

6.  Differential effect of cancer on the serum protein binding to mianserin and imipramine.

Authors:  I Torres; E Suárez; J M Rodríguez-Sasiain; C Aguirre; R Calvo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

7.  Orosomucoid serum concentrations and fat depot-specific mRNA and protein expression in humans.

Authors:  Assim A Alfadda; Sumbul Fatma; M Azhar Chishti; Mohammed Y Al-Naami; Ruba Elawad; Carmen Deanna O Mendoza; Hyunsun Jo; Yun Sok Lee
Journal:  Mol Cells       Date:  2011-11-29       Impact factor: 5.034

Review 8.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.

Authors:  I H Benedek; W D Fiske; W O Griffen; R M Bell; R A Blouin; P J McNamara
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

10.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.